CSL

Field Medical Advisor - Belgium

Belgium

Not SpecifiedCompensation
Junior (1 to 2 years)Experience Level
Full TimeJob Type
UnknownVisa
Pharmaceuticals, BiotechnologyIndustries

Requirements

Candidates should possess a Bachelor’s degree in Pharmacy, Biology, Medicine, or a related scientific field, and ideally have a strong understanding of the pharmaceutical industry. Demonstrated experience in medical affairs, sales, or a related role is preferred, along with excellent communication and interpersonal skills.

Responsibilities

The Field Medical Advisor will represent Medical Affairs externally, building and maintaining relationships with Key Opinion Leaders (KOLs) and healthcare professionals (HCPs) within Belgium. They will provide medical information, disease state education, and scientific support to internal and external stakeholders, including training colleagues and participating in cross-functional team meetings. The role involves developing scientific expertise, identifying and mapping HCPs, facilitating scientific engagement, and supporting medical activities such as advisory boards and congress symposia. Furthermore, the advisor will contribute to Market Access dossiers, provide medical support for patient access, and ensure compliance with all applicable regulations and policies.

Skills

Medical Affairs
Relationship Building
KOL Engagement
HCP Engagement
Scientific Communication
Clinical Data Analysis
Medical Education
Regulatory Compliance
Therapeutic Area Knowledge

CSL

Develops biotherapies and influenza vaccines

About CSL

CSL develops and delivers biotherapies and influenza vaccines, focusing on rare and serious diseases. Their products include plasma-derived and recombinant therapies, which are created through extensive research and development. CSL serves a wide range of clients, including healthcare providers and governments, across the Americas, Asia Pacific, and Europe. What sets CSL apart from competitors is its comprehensive portfolio and commitment to addressing rare diseases, alongside a strong emphasis on diversity and inclusion within its workforce. The company's goal is to save lives and protect health through its innovative therapies and vaccines.

Key Metrics

Parkville, AustraliaHeadquarters
1916Year Founded
$2,628.7MTotal Funding
ACQUISITIONCompany Stage
Biotechnology, HealthcareIndustries
10,001+Employees

Risks

Emerging synthetic biomaterials may reduce demand for traditional plasma therapies.
Jumar Bioincubator could increase local competition in the biotech sector.
CSL may need to adapt to the rising effectiveness of cell-based influenza vaccines.

Differentiation

CSL offers the broadest range of plasma-derived and recombinant therapies globally.
CSL's self-amplifying mRNA COVID-19 vaccine provides longer immunity at lower doses.
CSL's MF59® adjuvant enhances immune response, crucial for pandemic preparedness.

Upsides

CSL's garadacimab could be the first monthly treatment for hereditary angioedema.
CSL's cell-based influenza vaccine shows higher effectiveness over egg-based vaccines.
CSL's gene therapy HEMGENIX® offers a one-time treatment for haemophilia B.

Land your dream remote job 3x faster with AI